Inovio Pharmaceuticals(US:INO) Globenewswire·2026-03-27 22:09Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Inovio securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] Group 2: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing and the likelihood of submitting the INO-3107 Biologics License Application to the FDA [4] - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [4] - The lawsuit asserts that when the true details became public, investors suffered damages due to the misleading statements made by the defendants [4]